cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5281/zenodo.3234158
title: Analysis of Huntingtin BioID Datasets 2019/04/09

description: <strong>Project: </strong>Investigation of putative HTT interacting proteins

<strong>Experiment: </strong>Analysis of HTT BioID datasets 

<strong>Date completed:­ </strong>2019/04/09

<strong>Rationale: </strong>BioID technology employs a promiscuous biotin ligase (BirA) fused to the terminus of the target protein, huntingtin, allowing proximal proteins to be biotinylated and then subsequently identified through mass spectrometry experiments. This technique has not been applied to assess huntingtin interactors to date in the published literature, so will provide a novel methodology to characterize the huntingtin interactome. As huntingtin is a large protein molecule and the precise location of the N and C-termini remain unresolved due to their flexible nature, both N and C terminally BirA-tagged constructs for full-length huntingtin will be generated for overexpression as well as a truncated construct spanning amino acids 80-3100, the region of the protein resolved in the recent cryo-electron microscopy structure which omits the flexible termini. Huntingtin fusion proteins will be overexpressed in cells subjected to different ROS stresses as well as control conditions. Resultant cell lysates will be analysed through collaboration with Prof. Anne-Claude Gingras (Lunenfeld Tanenbaum Research Institute, University of Toronto). From this work, we hope to obtain a list of putative huntingtin interactors which will be compared to previously published findings and assessed for stable complex formation with huntingtin
description: Dr. Harding is the recipient of the Huntington's Disease Society of America Berman Topper Career Development Fellowship which funds and supports this research, in addition to generous funding from the CHDI Foundation and the Huntington Society of Canada. The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.
DOI: 10.5281/zenodo.3234159
title: Analysis of Huntingtin BioID Datasets 2019/04/09

description: <strong>Project: </strong>Investigation of putative HTT interacting proteins

<strong>Experiment: </strong>Analysis of HTT BioID datasets 

<strong>Date completed:­ </strong>2019/04/09

<strong>Rationale: </strong>BioID technology employs a promiscuous biotin ligase (BirA) fused to the terminus of the target protein, huntingtin, allowing proximal proteins to be biotinylated and then subsequently identified through mass spectrometry experiments. This technique has not been applied to assess huntingtin interactors to date in the published literature, so will provide a novel methodology to characterize the huntingtin interactome. As huntingtin is a large protein molecule and the precise location of the N and C-termini remain unresolved due to their flexible nature, both N and C terminally BirA-tagged constructs for full-length huntingtin will be generated for overexpression as well as a truncated construct spanning amino acids 80-3100, the region of the protein resolved in the recent cryo-electron microscopy structure which omits the flexible termini. Huntingtin fusion proteins will be overexpressed in cells subjected to different ROS stresses as well as control conditions. Resultant cell lysates will be analysed through collaboration with Prof. Anne-Claude Gingras (Lunenfeld Tanenbaum Research Institute, University of Toronto). From this work, we hope to obtain a list of putative huntingtin interactors which will be compared to previously published findings and assessed for stable complex formation with huntingtin
description: Dr. Harding is the recipient of the Huntington's Disease Society of America Berman Topper Career Development Fellowship which funds and supports this research, in addition to generous funding from the CHDI Foundation and the Huntington Society of Canada. The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.
DOI: 10.5281/zenodo.3234163
title: Analysis of dephosphorylated HTT samples for cryoEM analysis and further sample preparation 2019/04/15

description: <strong>Project: </strong>High resolution structural analysis of purified HTT samples

<strong>Experiment: </strong>Analysis of dephosphorylated HTT samples for cryoEM analysis and further sample preparation

<strong>Date completed:­ </strong>2019/04/15

<strong>Rationale: </strong>We now have a good understanding of the global structure of HTT when in complex with HAP40 and our MALS and SAXS data suggest that apo HTT is likely self-associating and heterogenous in nature, despite high levels of purity. Dephosphorylating HTT from Sf9 cell production could alter its global structure sufficiently to allow high resolution structure determination by cryoEM.
description: Dr. Harding is the recipient of the Huntington's Disease Society of America Berman Topper Career Development Fellowship which funds and supports this research, in addition to generous funding from the CHDI Foundation and the Huntington Society of Canada. The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.
DOI: 10.5519/qd.1rx1f3yj
title: Query on the Natural History Museum Data Portal (data.nhm.ac.uk) (16 records)
DOI: 10.5519/qd.en5wl1dx
title: Query on the Natural History Museum Data Portal (data.nhm.ac.uk) (33 records)
DOI: 10.5519/qd.pjyptmry
title: Query on the Natural History Museum Data Portal (data.nhm.ac.uk) (16 records)
DOI: 10.5281/zenodo.3234162
title: Analysis of dephosphorylated HTT samples for cryoEM analysis and further sample preparation 2019/04/15

description: <strong>Project: </strong>High resolution structural analysis of purified HTT samples

<strong>Experiment: </strong>Analysis of dephosphorylated HTT samples for cryoEM analysis and further sample preparation

<strong>Date completed:­ </strong>2019/04/15

<strong>Rationale: </strong>We now have a good understanding of the global structure of HTT when in complex with HAP40 and our MALS and SAXS data suggest that apo HTT is likely self-associating and heterogenous in nature, despite high levels of purity. Dephosphorylating HTT from Sf9 cell production could alter its global structure sufficiently to allow high resolution structure determination by cryoEM.
description: Dr. Harding is the recipient of the Huntington's Disease Society of America Berman Topper Career Development Fellowship which funds and supports this research, in addition to generous funding from the CHDI Foundation and the Huntington Society of Canada. The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.
DOI: 10.17632/nvf3b8vttm.1
title: Data for: Benchmark analysis of coupled neutron/decay-gamma transport method NASCA for shutdown dose rate calculation

description: These data are plot of decay gamma spectrum and comparison among other SDDR computational codes
DOI: 10.5281/zenodo.3234166
title: Analysis of dephosphorylated HTT samples by cryoEM analysis 2019/05/01

description: <strong>Project: </strong>High resolution structural analysis of purified HTT samples

<strong>Experiment: </strong>Analysis of dephosphorylated HTT samples by cryoEM analysis 

<strong>Date completed:­ </strong>2019/05/01

<strong>Rationale: </strong>We now have a good understanding of the global structure of HTT when in complex with HAP40 and our MALS and SAXS data suggest that apo HTT is likely self-associating and heterogenous in nature, despite high levels of purity. Dephosphorylating HTT from Sf9 cell production could alter its global structure sufficiently to allow high resolution structure determination by cryoEM.
description: Dr. Harding is the recipient of the Huntington's Disease Society of America Berman Topper Career Development Fellowship which funds and supports this research, in addition to generous funding from the CHDI Foundation and the Huntington Society of Canada. The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.
DOI: 10.5281/zenodo.3234167
title: Analysis of dephosphorylated HTT samples by cryoEM analysis 2019/05/01

description: <strong>Project: </strong>High resolution structural analysis of purified HTT samples

<strong>Experiment: </strong>Analysis of dephosphorylated HTT samples by cryoEM analysis 

<strong>Date completed:­ </strong>2019/05/01

<strong>Rationale: </strong>We now have a good understanding of the global structure of HTT when in complex with HAP40 and our MALS and SAXS data suggest that apo HTT is likely self-associating and heterogenous in nature, despite high levels of purity. Dephosphorylating HTT from Sf9 cell production could alter its global structure sufficiently to allow high resolution structure determination by cryoEM.
description: Dr. Harding is the recipient of the Huntington's Disease Society of America Berman Topper Career Development Fellowship which funds and supports this research, in addition to generous funding from the CHDI Foundation and the Huntington Society of Canada. The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.
DOI: 10.14469/hpc/5711
title: 1,1,3,3-tetrakis(4-carboxyphenyl)-1,3-dimethyldisiloxane_L3-H4

description: 1,1,3,3-tetrakis(4-carboxyphenyl)-1,3-dimethyldisiloxane_L3-H4
DOI: 10.14469/hpc/5712
title: Bis(4-bromophenyl)methylsilane_C21

description: Bis(4-bromophenyl)methylsilane_C21
DOI: 10.14469/hpc/5713
title: 1,1,3,3-tetrakis(4-bromophenyl)-1,3-dimethyldisiloxane_C24

description: 1,1,3,3-tetrakis(4-bromophenyl)-1,3-dimethyldisiloxane_C24
DOI: 10.5281/zenodo.3234171
title: Coexpression and purification of HTT and HTT-HAP40 with NEDD4L and HAP1 2019/05/02

description: <strong>Project: </strong>Biophysical investigation of purified HTT protein and protein complex samples

<strong>Experiment: </strong>Coexpression and purification of HTT and HTT-HAP40 with NEDD4L and HAP1

<strong>Date completed:­ </strong>2019/05/02

<strong>Rationale: </strong>HAP1 and NEDD4L have been suggested as high probability interaction partners of HTT although it is unclear if they interact with HTT or HTT-HAP40. Coexpression of the constructs was conducted in baculoviral expression system (Sf9 cells) to determine if they copurify with HTT or HTT-HAP40.
description: Dr. Harding is the recipient of the Huntington's Disease Society of America Berman Topper Career Development Fellowship which funds and supports this research, in addition to generous funding from the CHDI Foundation and the Huntington Society of Canada. The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.
DOI: 10.5281/zenodo.3234172
title: Coexpression and purification of HTT and HTT-HAP40 with NEDD4L and HAP1 2019/05/02

description: <strong>Project: </strong>Biophysical investigation of purified HTT protein and protein complex samples

<strong>Experiment: </strong>Coexpression and purification of HTT and HTT-HAP40 with NEDD4L and HAP1

<strong>Date completed:­ </strong>2019/05/02

<strong>Rationale: </strong>HAP1 and NEDD4L have been suggested as high probability interaction partners of HTT although it is unclear if they interact with HTT or HTT-HAP40. Coexpression of the constructs was conducted in baculoviral expression system (Sf9 cells) to determine if they copurify with HTT or HTT-HAP40.
description: Dr. Harding is the recipient of the Huntington's Disease Society of America Berman Topper Career Development Fellowship which funds and supports this research, in addition to generous funding from the CHDI Foundation and the Huntington Society of Canada. The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.
DOI: 10.5281/zenodo.3234173
title: Large-scale stringent purification of HTT-HAP40 using heparin affinity chromatography 2019/05/12

description: <strong>Project: </strong>Biophysical investigation of purified HTT protein samples

<strong>Experiment: </strong>Large-scale stringent purification of HTT-HAP40 using heparin affinity chromatography

<strong>Date completed:­ </strong>2019/05/12

<strong>Rationale: </strong>Previous attempts to generate a much purer and homogenous HTT-HAP40 sample showed that the complex can bind heparin resin. In small-scale experiment, I also incorporated helpful suggestions from scientists at the CHDI Palm Springs meeting full-length HTT research breakout group i.e. ATP wash to remove HSP proteins. The experiment included 3 affinity chromatography steps with FLAG, heparin and NiNTA resin and finally a gel filtration step and yielded a highly pure HTT-HAP40 sample: https://zenodo.org/record/2628064.
description: Dr. Harding is the recipient of the Huntington's Disease Society of America Berman Topper Career Development Fellowship which funds and supports this research, in addition to generous funding from the CHDI Foundation and the Huntington Society of Canada. The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.
DOI: 10.5281/zenodo.3234174
title: Large-scale stringent purification of HTT-HAP40 using heparin affinity chromatography 2019/05/12

description: <strong>Project: </strong>Biophysical investigation of purified HTT protein samples

<strong>Experiment: </strong>Large-scale stringent purification of HTT-HAP40 using heparin affinity chromatography

<strong>Date completed:­ </strong>2019/05/12

<strong>Rationale: </strong>Previous attempts to generate a much purer and homogenous HTT-HAP40 sample showed that the complex can bind heparin resin. In small-scale experiment, I also incorporated helpful suggestions from scientists at the CHDI Palm Springs meeting full-length HTT research breakout group i.e. ATP wash to remove HSP proteins. The experiment included 3 affinity chromatography steps with FLAG, heparin and NiNTA resin and finally a gel filtration step and yielded a highly pure HTT-HAP40 sample: https://zenodo.org/record/2628064.
description: Dr. Harding is the recipient of the Huntington's Disease Society of America Berman Topper Career Development Fellowship which funds and supports this research, in addition to generous funding from the CHDI Foundation and the Huntington Society of Canada. The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.
DOI: 10.18739/a2hx15q8v
title: Thermal State of Permafrost in North America - annually observed ground temperatures, 2018
DOI: 10.18739/a2d795976
title: Thermal State of Permafrost in North America - continuously observed ground temperatures, 2017-2018
DOI: 10.5281/zenodo.3052407
title: Results from the monitoring of veterinary medicinal product residues and other substances in live animals and animal products - Spain

description: This dataset contains the monitoring results of veterinary medicinal product residues and other substances measured in live animals and animal products analysed by the national competent authority of Spain. The presence of unauthorised substances, residues of veterinary medicinal products or chemical contaminants in food may pose a risk factor for public health.

For this reason and in order to ensure a high level of consumer protection, a comprehensive legislative framework has been established in the European Union (EU) which defines maximum limits permitted in food and monitoring programmes for the control of the presence of these substances in the food chain. Regulation (EU) No 37/2010 establishes maximum limits for residues of veterinary medicinal products in food-producing animals and animal products. Maximum residue levels for pesticides in or on food and feed of plant and animal origin are laid down in Regulation (EC) No 396/2005. Commission Regulation (EC) 1881/2006 lays down the maximum limits for the presence of certain contaminants in animal products. Council Directive 96/23/EC lays down measures to monitor certain substances and residues thereof, mainly veterinary medicinal products, in live animals and animal products. Additionally, Commission Decision 97/747/EC lays down levels and frequencies of sampling for certain animal products.

The dataset contains the results of laboratory tests from samples taken from bovines, pigs, sheep, goats, horses, poultry, rabbits, farmed game, wild game aquaculture, milk, eggs and honey.

Targeted samples are taken with the aim of detecting illegal treatment or controlling compliance with the maximum levels laid down in the relevant legislation. This means that, in their national plans Member States target the groups of animals (species, gender, age) where the probability of finding residues is the highest.

Suspect samples are taken as a consequence of i) non-compliant results on samples taken in accordance with the monitoring plan, ii) possession or presence of prohibited substances at any point during manufacture, storage, distribution or sale through the food and feed production chain, or iii) suspicion or evidence of illegal treatment or non-compliance with the withdrawal period for an authorised medicinal veterinary product.

Residues of pharmacologically active substances mean active substances, excipients or degradation products and their metabolites, which remain in food.

Unauthorised substances or products mean substances or products prohibited under European Union legislation.

Non-compliant sample is a sample that has been analysed for the presence of one or more substances and failed to comply with the legal provisions for at least one substance. Thus, a sample can be non-compliant for one or more substances.
description: EU; CSV; data.collection@efsa.europa.eu
DOI: 10.5281/zenodo.3234030
title: Prince Edward Island (Canada) Predictive Soil Mapping data set (30 m)

description: Prince Edward Island (Canada) Predictive Soil Mapping data set. Training points include:


	soil organic matter (624 points): unit: percent, g/100g ) samples from the topsoil (0-23 cm depth),
	soil types (672 points),


Covariate layers include:


	DEM derivatives (Channel_Network_Base_Level.tif, MRRTF.tif, Relative_Slope_Position.tif, Slope.tif, TWI.tif, Valley_Depth.tif, Vertical_Distance_To_Channel_Network.tif),
	landcover_2016_reclassify.tif (categorical values),
	DSS_soil_polygons.tif (soil polygons),


Some covariates are type numeric, some type factor. To use the pre-processed data download only the RDS file. E.g. "PEI100m.soil.rds" contains all covariates layers resampled to 100 m resolution and all training points.
description: {"references": ["Nyiraneza, J., Thompson, B., Geng, X., He, J., Jiang, Y., Fillmore, S., & Stiles, K. (2017). Changes in soil organic matter over 18 yr in Prince Edward Island, Canada. Canadian journal of soil science, 97(4), 745-756."]}
DOI: 10.5281/zenodo.3234031
title: Prince Edward Island (Canada) Predictive Soil Mapping data set (30 m)

description: Prince Edward Island (Canada) Predictive Soil Mapping data set. Training points (soil organic matter and soil types) and 30 m resolution covariates. Covariates include:


	DEM derivatives (Channel_Network_Base_Level.tif, MRRTF.tif, Relative_Slope_Position.tif, Slope.tif, TWI.tif, Valley_Depth.tif, Vertical_Distance_To_Channel_Network.tif),
	landcover_2016_reclassify.tif (categorical values),
	DSS_soil_polygons.tif (soil polygons),
description: {"references": ["Nyiraneza, J., Thompson, B., Geng, X., He, J., Jiang, Y., Fillmore, S., & Stiles, K. (2017). Changes in soil organic matter over 18 yr in Prince Edward Island, Canada. Canadian journal of soil science, 97(4), 745-756."]}
DOI: 10.7910/dvn/tqlypf/hmqwqw
title: Jeehp16_13_raw data.xlsx

description: :unav